Dupuytren’s disease—etiology and treatment

Ruettermann, Mike; Hermann, Robert Michael; Khatib-Chahidi, Karl; Werker, Paul M. N.

doi:10.3238/arztebl.m2021.0325

Cited by 18 publications

(23 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It can be argued that, in contrast to surgical fasciectomy, collagenase injection is a simple minimally invasive treatment and, therefore, repeat injections should not be considered as failure but as part of the treatment method. In fact it has been suggested that recurrences should be considered part of the disease and not as failure [ 16 ]. However, as many patients may consider the need for repeat injections as treatment failure, thorough pre-treatment information about the risks and benefits of different treatment options is important to allow patients make informed decisions regarding treatment choices.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Long-Term Contracture Recurrence after Collagenase Injection for Dupuytren Disease: A Prospective Cohort Study

et al. 2023

View full text Add to dashboard Cite

In Dupuytren disease, little is known about the long-term outcomes of collagenase injection or risk factors for contracture recurrence. In this prospective study, 159 patients (242 fingers) with Dupuytren disease and active extension deficit (AED) ≥20° in a metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint were treated with collagenase injection during a 14-month period. At 5 years, 18 patients were deceased, 2 could not be contacted, and 13 had undergone fasciectomy. The remaining 126 patients (199 treated fingers) participated in a follow-up evaluation at 52–96 (mean 65) months after injection, with physical examination (114 patients) or telephone interview (12 patients). Recurrence was defined as subsequent treatment (surgery or repeat injection) or ≥20° AED worsening in a treated joint between the 6-week and 5-year measurements. The mean AED at baseline was 42° (SD 24) for MCP joints and 31° (SD 29) for PIP joints and at 5 years 11° (SD 17) and 17° (SD 23), respectively. Recurrence occurred in 17% of MCP joints and 25% of PIP joints. Statistically significant risk factors for PIP joint contracture recurrence were greater baseline AED (odds ratio 1.04, 95% CI 1.02–1.06) and small finger treatment (OR 4.6, 95% CI 1.5–14.3), with no significant risk factors found for MCP contracture recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk Factors for Long-Term Contracture Recurrence after Collagenase Injection for Dupuytren Disease: A Prospective Cohort Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Fibrotic ligament diseases (FLDs) are commonly seen in many countries all around the world and include adhesive capsulitis, carpal tunnel syndrome, Dupuytren's disease, cubital tunnel syndrome, arthrofibrosis, and scleroderma. There are similar pathological changes in the abovementioned areas: the excessive accumulation of fibrotic tissue (Bournia et al, 2009; Kang treatment could eliminate the scarring but did not prevent the risk of recurrence (Neviaser and Hannafin, 2010;Padua et al, 2016;Ruettermann et al, 2021;Zhao et al, 2022a). Recently, multiple studies had reported that relaxin had the potential to inhibit fibrosis formation and reduce the risk of developing fibrosis by regulate collagen production and degradation (Bournia et al, 2009;Kang et al, 2014;Kang et al, 2017;Blessing et al, 2019;Ko et al, 2019).…”

Section: Introductionmentioning

confidence: 97%

“…Currently, most non-surgical treatments, including physical therapy, oral anti-inflammatory drugs, and topical steroid injections, fail to reduce collagen production and accelerate collagen degradation to reverse the progression of fibrosis in the long term. Surgical treatment could eliminate the scarring but did not prevent the risk of recurrence ( Neviaser and Hannafin, 2010 ; Padua et al, 2016 ; Ruettermann et al, 2021 ; Zhao et al, 2022a ). Recently, multiple studies had reported that relaxin had the potential to inhibit fibrosis formation and reduce the risk of developing fibrosis by regulate collagen production and degradation ( Bournia et al, 2009 ; Kang et al, 2014 ; Kang et al, 2017 ; Blessing et al, 2019 ; Ko et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism

Yuan

Guo

Liang

et al. 2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Fibrotic ligament diseases (FLDs) are diseases caused by the pathological accumulation of periarticular fibrotic tissue, leading to functional disability around joint and poor life quality. Relaxin (RLX) has been reported to be involved in the development of fibrotic lung and liver diseases. Previous studies have shown that RLX can block pro-fibrotic process by reducing the excess extracellular matrix (ECM) formation and accelerating collagen degradation in vitro and in vivo. Recent studies have shown that RLX can attenuate connective tissue fibrosis by suppressing TGF-β/Smads signaling pathways to inhibit the activation of myofibroblasts. However, the specific roles and mechanisms of RLX in FLDs remain unclear. Therefore, in this review, we confirmed the protective effect of RLX in FLDs and summarized its mechanism including cells, key cytokines and signaling pathways involved. In this article, we outline the potential therapeutic role of RLX and look forward to the application of RLX in the clinical translation of FLDs.

show abstract

“…Palmar fibromatosis (also known as Dupuytren's Disease) is a benign proliferative disorder of the palmar fascia which leads to the formation of cords and nodules and progressive contracture of the fingers and thumb and consequently affects hand function [1][2][3][4] . Genetic, immunological and environmental factors interact to promote the development of palmar fibromatosis [5][6][7] .…”

Section: Introductionmentioning

confidence: 99%

A typical presentation of palmar fibromatosis in adult female: A case report

Almigdad¹,

Mustafa²,

Ahmad³

et al. 2022

Int. J. Case Rep. Orthop.

View full text Add to dashboard Cite

Palmar fibromatosis is a benign proliferative disorder of the palmar fascia which leads to the formation of cords and nodules and progressive contracture of the fingers and thumb and consequently affects hand function. In this review, we report an atypical presentation of palmar fibromatosis in a thirty-one-year lady who underwent surgical excision for a mass in the second interphalangeal web space extending to the middle finger's radial side. The histopathological study of excised mass was compatible with the diagnosis of palmar fibromatosis.

show abstract

Dupuytren’s disease—etiology and treatment

Cited by 18 publications

References 54 publications

Risk Factors for Long-Term Contracture Recurrence after Collagenase Injection for Dupuytren Disease: A Prospective Cohort Study

Risk Factors for Long-Term Contracture Recurrence after Collagenase Injection for Dupuytren Disease: A Prospective Cohort Study

Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism

A typical presentation of palmar fibromatosis in adult female: A case report

Contact Info

Product

Resources

About